NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Recursion Pharmaceuticals reported financial results for the second quarter ending June 30, 2022.
Recursion Pharmaceuticals reported a revenue of $7.7 million for the second quarter of 2022, compared to $2.5 million for the second quarter of 2021. Net loss was $65.6 million for the second quarter of 2022, compared to a net loss of $43.4 million for the second quarter of 2021. Cash, cash equivalents and investments were $515.4 million as of June 30, 2022.
- Actively enrolling participants in Phase 2/3 clinical trial for NF2-mutated meningiomas.
- On track to initiate Phase 2 clinical trial for FAP in the third quarter of 2022.
- U.S. FDA granted Fast Track designation and the European Commission granted Orphan Drug Designation for REC-4881 for FAP.
- On track to initiate Phase 1 clinical trial for Clostridium difficile colitis in the second half of 2022.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$7.67M
Revenue by segment
Recursion Pharmaceuticals · $7.7M total across 1 segment · Q2 2022
- Collaboration Revenue$7.7M+208.0%100.0%
Forward guidance
Recursion continues to make progress in advancing its clinical programs and leading the digital transformation of drug discovery.
Tailwinds
- Initiating a Phase 2 trial for NF2-mutated meningiomas.
- Receiving U.S. FDA Fast Track and European Commission Orphan Drug designations for REC-4881 for the potential treatment of FAP.
- Focusing pipeline around rapidly deliverable oncology programs.
- Building additional capabilities into our Recursion OS platform.
- Scaling transcriptomics hit validation platform to up to 13 thousand near-whole exomes per week.
Headwinds
- Continued capital markets friction.
- Challenges inherent in pharmaceutical research and development.
- Risk of failure in preclinical and clinical programs.
- Ability to obtain financing for development activities and other corporate purposes.
- Impact of the COVID-19 pandemic and force majeure events.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro